Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

Inclusion Criteria:

- ≥ 18 yrs), male or female subject

- Disease duration since diagnosis ≥ 3 months and ≤ 24 months as based on the
Classification Criteria for Psoriatic Arthritis (CASPAR),

- SJC AND TJC must be >1 and ≤ 4

- For all regions, the local Regulatory Label for treatment with apremilast must be
followed.

- Stable doses of protocol-allowed PsA medications

- General good health (except for psoriatic arthritis) as judged by the Investigator,
based on medical history, physical examination, and clinical laboratories. (Note: The
definition of good health means a subject does not have uncontrolled significant
comorbid conditions).

- Comply with protocol-required contraception measures

Exclusion Criteria:

- Prior use of >1 as DMARD.

- Prior exposure to a JAK-inhibitor and/or a biologic DMARD.

- Use of intra-articular (IA) or intra-muscular (IM) glucocorticoid injection within 8
weeks before the Baseline Visit.

- Use of leflunomide within 12 weeks of randomization. Subjects who stopped leflunomide
and completed 11 days of treatment with cholestyramine (8 g, 3 x daily) prior to the
Baseline Visit may enter the study.

- Prior use of cyclosporine.

- Prior treatment with apremilast, or participation in a clinical study, involving
apremilast.

- Use of any investigational drug within 4 weeks of the Baseline Visit, or 5
pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).